FML-Neo Liquifilm
FML-Neo Liquifilm is a medicine authorised by Swissmedic under authorisation number 38174. The authorisation holder is AbbVie AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 01 April 1974 and the authorisation is valid without a time limit. The export lists no ATC code for this medicine.
| Authorisation number | 38174 |
|---|---|
| Name | FML-Neo Liquifilm |
| Full name | FML-Neo Liquifilm, Augentropfensuspension |
| Authorisation holder | AbbVie AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | not stated |
| First authorisation | 01 April 1974 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | FML-Neo Liquifilm, Augentropfensuspension | A | 01 April 1974 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| The Swissmedic export lists no pack sizes for this medicine. | |||||
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is FML-Neo Liquifilm authorised in Switzerland?
Yes. FML-Neo Liquifilm is authorised by Swissmedic under authorisation number 38174, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does FML-Neo Liquifilm have?
FML-Neo Liquifilm is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of FML-Neo Liquifilm?
The authorisation holder is AbbVie AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.